Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores

Hepatology

Metabolic associated fatty liver disease increases COVID-19 disease severity in non-diabetic patients

J Gastroenterol Hepatol.

Gao F, Zheng KI, Wang XB, Yan HD, Sun QF, Pan KH, Wang TY, Chen YP, George J, Zheng MH

doi: 10.1111/jgh.15112.

Hepatology

Nonalcoholic Fatty Liver Disease Increases Risk of Incident Chronic Kidney Disease: a Systematic Review and Meta-Analysis

Metabolism.

Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, Targher G

doi: 10.1016/j.metabol.

Hepatology

Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study

Clin Gastroenterol Hepatol.

Baratta F, Pastori D, Angelico F, Balla A, Paganini AM, Cocomello N, Ferro D, Violi F, Sanyal AJ, Del Ben M

doi: 10.1016/j.cgh.2019.12.026.

Further Publications

Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States

J Hepatol

Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A

doi: 10.1016/j.jhep.2021.07.035

Hepatology

A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores

Clin Gastroenterol Hepatol

De Vincentis A, Tavaglione F, Jamialahmadi O, Picardi A, Antonelli-Incalzi R, Valenti L, Romeo S, Vespasiani-Gentilucci U

doi: 10.1016/j.cgh.2021.05.056

Hepatology

Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease

J Hepatol.

Nascimbeni F, Bedossa P, Fedchuk L, Pais R, Charlotte F, Lebray P, Poynard T, Ratziu V

doi: 10.1016/j.jhep.2019.12.008.

Further Publications

Metabolic dysfunction associated fatty liver disease improves detection of high liver stiffness: The rotterdam study

Hepatology

van Kleef L, Ayada I, Alferink L, Pan Q, de Knegt R

doi: 10.1002/hep.32131

Hepatology

Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease

J Gastroenterol.

Kakisaka K, Suzuki Y, Fujiwara Y, Abe T, Yonezawa M, Kuroda H, Ishida K, Sugai T, Takikawa Y

doi: 10.1007/s00535-018-1468-9.

Hepatology

The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease

BMC Gastroenterol.

Trembling PM, Apostolidou S, Gentry-Maharaj A, Parkes J, Ryan A, Tanwar S, Burnell M, Harris S, Menon U, Rosenberg WM

doi: 10.1186/s12876-020-01251-w.

Related content

Metabolic associated fatty liver disease increases COVID-19 disease severity in non-diabetic patients

Nonalcoholic Fatty Liver Disease Increases Risk of Incident Chronic Kidney Disease: a Systematic Review and Meta-Analysis

Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study

Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States

A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores

Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease

Metabolic dysfunction associated fatty liver disease improves detection of high liver stiffness: The rotterdam study

Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease

The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease